Boutique Venture Partners

Surge is an immunological model capable of predicting postoperative infections. The company combines a single-cell assessment of the immune system before surgery with clinical data using a proprietary machine-learning algorithm. By analyzing the millions of immune cells in a small amount of blood, the platform can mimic surgical trauma in a test tube before surgery.

miRecule™ is a biotechnology company developing Antibody RNA Conjugate (ARC) therapies for cancer and muscular dystrophy. Our approach to drug design revolves around using genomic patient data to create highly tailored therapeutics designed to help patients live a life free from the debilitating symptoms of their disorders. Our proprietary DREAmiR™ platform utilizes genomic and outcome data from thousands of patients to identify underlying genetic changes that cause their disease, and then creates a novel RNA therapeutic that can directly target and fix that genetic abnormality. miRecule is currently applying the DREAmiR™ platform to develop first-in-class therapies, with lead programs in Head & Neck Cancer and Facioscapulohumeral Muscular Dystrophy.

Docbot is an artificial intelligence technology company focusing on gastrointestinal (GI) diseases. Docbot’s products are built on the UltivisionAI software platform for real-time image analysis, automated reporting, and analytic tools to improve patient care and clinical workflows. Docbot's mission is to provide the most powerful AI-assisted image analysis solutions to revolutionize GI care.

FluidAI Medical is a medical platform company at the forefront of revolutionizing global patient care, leveraging the transformative power of artificial intelligence in post-operative recovery.

Mesentech is a company focused on treating diseases and medical conditions that relate to bone. They are generating a series of products, from different, but complementary approaches that will effectively address currently difficult to treat conditions. Bone can be one of the most difficult organs to access and treat with medicines. It’s hard surface and low porosity presents challenges in adequately getting drugs to either the bone surface or to its interior. Treatment often requires administering high doses of a drug over extended periods. Not only is achievement of efficacy compromised, but also side- effects may be more prevalent and can limit treatment effectiveness. Mesentech’s lead technology is a proprietary bone targeting system that can effectively deliver small-molecule and biological drugs to the surface or to the interior of bone. Pre-clinical in-vivo models have confirmed the utility of this technology.

Zeda (formerly PrinterPrezz / Vertex Manufacturing) is a leading technology solutions company. Our objective is to better lives by investing in cutting-edge technologies, innovative companies, and groundbreaking ideas. Our foundation combines expertise from diverse industries, including AM, nanotech, precision manufacturing, and incubating new ideas. Servicing highly regulated industries such as medical, space, defense, and aerospace, Zeda’s mission is to build it all better together.

Docbot is an artificial intelligence technology company focusing on gastrointestinal (GI) diseases. Docbot’s products are built on the UltivisionAI software platform for real-time image analysis, automated reporting, and analytic tools to improve patient care and clinical workflows. Docbot's mission is to provide the most powerful AI-assisted image analysis solutions to revolutionize GI care.

miRecule™ is a biotechnology company developing Antibody RNA Conjugate (ARC) therapies for cancer and muscular dystrophy. Our approach to drug design revolves around using genomic patient data to create highly tailored therapeutics designed to help patients live a life free from the debilitating symptoms of their disorders. Our proprietary DREAmiR™ platform utilizes genomic and outcome data from thousands of patients to identify underlying genetic changes that cause their disease, and then creates a novel RNA therapeutic that can directly target and fix that genetic abnormality. miRecule is currently applying the DREAmiR™ platform to develop first-in-class therapies, with lead programs in Head & Neck Cancer and Facioscapulohumeral Muscular Dystrophy.

QMENTA is a software platform for imaging-based clinical studies. Their solutions include data management systems, clinical trials, neuroimaging disease packages, neuro research, clinical care, and neuro-data services. Their cloud-based software solutions enable and build medical imaging management.

Smartlens is a clinical-stage Med Tech company with a portfolio of technologies to treat and diagnose Glaucoma - a chronic eye disease and the leading cause of irreversible blindness. The Company is running clinical trials with its novel eye pressure (IOP) monitoring contact lens (miLens) that will help improve clinical outcomes in Glaucoma. The disease affects hundreds of millions around the globe; even in developed countries more than 50% of the patients are currently undiagnosed, and more than 38% are going blind despite being treated. The need for monitoring eye pressure outside the clinic has been defined as an urgent need by scientific, medical, and industry leaders in ophthalmology that will help improve clinical outcomes. Smartlens’ flagship product miLens is a non-invasive and convenient way of monitoring eye pressure for anyone anywhere at any time. It will help improve early diagnosis, enable personalized treatments, and disease monitoring thus reducing the prevalence of blindness, treatment costs, and its huge burden on lives and economies. miLens is utilizing a novel, electronics-free sensor technology that is fully owned by Smartlens, Inc. and protected by its portfolio of issued and pending patents covering more than 40 countries. The Company's novel technology is also being studied at Stanford University Labs for monitoring (ICP) which is associated with certain neurological disorders, and cancers. Smartlens also owns a non-invasive drug delivery technology that monitors the IOP and releases the right medication at the right time which will help improve efficacy, patient compliance and reduce the side effects. Smartlens is the Winner of the 2021 "Outstanding Innovation in Medical Technology and Life Sciences" of High-Tech Awards by Octane. The Company has been invited to various national and international conferences, published its studies, listed among the Top 10 MedTech Startups, and featured in ABC7, Fortune, BBC, and Nature Medicine.

Zeda (formerly PrinterPrezz / Vertex Manufacturing) is a leading technology solutions company. Our objective is to better lives by investing in cutting-edge technologies, innovative companies, and groundbreaking ideas. Our foundation combines expertise from diverse industries, including AM, nanotech, precision manufacturing, and incubating new ideas. Servicing highly regulated industries such as medical, space, defense, and aerospace, Zeda’s mission is to build it all better together.

Frontier Bio is creating lab-grown human tissues as an ethical replacement for animal studies and is setting the stage to eliminate the organ transplant waitlist.